GLPG5101*
CD19
CAR-T
Double-refractory, aggressive B-cell malignacies
Redefining the Future of Cancer Treatment
We are united around our mission to redefine the future of cancer treatment. Our goal is to help people facing cancer live longer, better lives. Our hope is fueled by the dream of a future free from cancer.
Unlocking hope
Addressing the unmet medical needs of cancer patients
Today, our oncology researchers passionately strive to turn cancers into manageable chronic conditions or even curable diseases.
Tomorrow, our hope is fueled by the dream of a future free from cancer. We are determined to shift the treatment paradigm of cancer.
The urgency for effective, broadly accessible treatment options and novel therapies is paramount, as the outlook for patients is often grim, with survival measured in months rather than years. That’s what fuels our ambition to redefine the future of cancer treatment.
SPEED
Speed is critical for cancer patients who cannot afford to wait to receive treatment
URGENCY
Urgent need for effective, broadly accessible treatment options and novel therapies is paramount
Driving pipeline growth and leveraging cross-modality synergies
Differentiated Technology Platforms
Small Molecules
– Excellence, speed, agility: fully-integrated, end-to-end in-house capabilities
– Best-in-class strategy: validated targets to develop differentiated medicines
– 25 years of experience: enhanced by external partnerships
Cell Therapy
– Scalable, decentralized, fast: fresh, fit, stem-like, early memory cells within a median vein-to-vein time of seven days
– High-yielding discovery engine: multi-targeting, next-generation cell therapies
– Diversify and grow: through partnerships and M&A
Our focus in oncology
Our current work is focused on the following hematological cancers for patients in need of additional and improved treatment options:
Non-Hodgkin’s lymphoma (NHL)
Chronic lymphocytic leukemia (CLL)
Multiple myeloma (MM)
Oncology Pipeline
Hematological tumors
Candidate
Target
Class
Indication
Discovery
IND/CTA Enabling
Phase 1
Phase 2
GLPG5301
BCMA
CAR-T
Relapsed/refractory multiple myeloma
Asset 1
Armored bi-specific
CAR-T
B-cell malignancies
Asset 2
Non-disclosed
CAR-T
Multiple myeloma
Solid tumors
Candidate
Target
Class
Indication
Discovery
IND/CTA Enabling
Phase 1
Phase 2
Uza-cel¹
MAGE-A4, expressing CD8α
TCR-T
Head & neck cancer
Asset 3
Non-disclosed
CAR-T
Small-cell lung cancer and neuro-endocrine
Asset 4
Non-disclosed
CAR-T
Platinum-resistant ovarian
1Collaboration with Adaptimmune
High-risk DLBCL with International Prognostic Index 3-5 or double/triple-hit lymphoma, primary refractory disease, defined as subjects failing to achieve a complete response to first-line anti-CD20 and anthracycline-based chemoimmunotherapy after ≥2 cycles at the interim disease assessment; IND: Investigational New Drug application; CTA: Clinical Trial Application; CAR T-cell therapy: Chimeric antigen receptor T cell therapy; TCR T-cell therapy: T cell receptor T cell therapy;
* Protocol for GLPG5101 currently being amended to include DLBCL-RT and CLL. We announced on February 12, 2025, that we are focusing our resources on accelerating GLPG5101 as our flagship CD19 CAR-T program. Pending the advancement of GLPG5101 in additional indications, we are deprioritizing activities for GLPG5201, our second CD19 CAR-T candidate.
Shifting the paradigm
Cell therapy
In 2022, we entered the field of cell therapy and antibody-therapy research and development through the acquisitions of CellPoint (in the Netherlands) and Abound Bio (in the U.S). The transactions provide us with end-to-end capabilities in cell therapy development and offer the potential for a paradigm shift in the space through the implementation of a breakthrough, decentralized manufacturing model and cutting-edge fully human antibody-based capabilities to design next-generation cell therapies.
Did you know?
Only 25%-30%* of eligible patients currently receive it due to
Limited capacity
Complex logistics
Restricted access
*Kourelis T, Bansal R, Patel KK, et al: Ethical challenges with CAR T slot allocation with idecabtagene vicleucel manufacturing access. J Clin Oncol 40, 2022 (16_suppl; abstr e20021); Hoffman MS, Hunter BD, Cobb PW, Varela JC, Munoz J. Overcoming barriers to referral for chimeric antigen receptor T cell therapy in patients with relapsed/refractory diffuse large B-cell lymphoma. Transplant Cell Ther. 2023;29(7):440-448. Mikhael J, Fowler J, and Shah N Chimeric Antigen Receptor T-Cell Therapies: Barriers and Solutions to Access. JCO Oncology Practice Vol 18, No 1
Fast, fresh, fit and stem-like
Our innovative approach to T-cell manufacturing near the point of care
Galapagos’ innovative decentralized cell therapy manufacturing platform has the potential for the administration of fresh, fit, stem-like, early memory cells within a median vein-to-vein time of seven days, greater physician visibility, and improved patient experience.
The platform consists of an end-to-end xCellit® workflow management and monitoring software system, a decentralized, functionally closed, automated manufacturing platform for cell therapies (using Lonza’s Cocoon®) and a proprietary quality control testing and release strategy.
Cell therapy in 7 days vein-to-vein
*GMP production at a compliant manufacturing facility located at the clinic premises or in close proximity to the clinic; The Cocoon® Platform is a registered trademark of Lonza Group AG
Decentralized manufacturing, close to patients
Our approach is based on a decentralized, functionally closed, automated manufacturing platform for cell therapies (using Lonza’s Cocoon® Platform). Discover more about it!
Pioneer with us in Oncology
This is your call for purpose!
Do you want to pioneer for patients in Oncology? Discover our vacancies!
Disease areas
More about our work in Immunology
We strive to accelerate innovation of transformational medicines that deliver more years of life and quality of life for patients and families living with cancer.
Partnerships
Work with us!
We combine internal and external innovation to add new capabilities, technologies and product candidates. Let’s start #PioneeringForPatients, together!